Report cover image

Monoclonal Antibody Therapeutics MarketSize by Production Method (In-Vitro, In-Vivo), Sources (Human, Chimeric), Route of Administration (Intravenous, Subcutaneous), Therapy (Inflammatory & Autoimmune, Oncology, Hematology))- Global Industry Analysis, Siz

Publisher Nova One Advisor
Published May 26, 2025
Length 453 Pages
SKU # ONEA20066981

Description

Monoclonal Antibody Therapeutics Market Size and Growth
The global monoclonal antibody therapeutics market size was valued at USD 233.19 billion in 2023 and is anticipated to reach around USD 919.06 billion by 2033, growing at a CAGR of 14.7% from 2024 to 2033.

Monoclonal Antibody Therapeutics Market Key Takeaways

North America accounted for the largest share of the monoclonal antibody therapeutics industry in 2023
In-Vitro segment held a dominant share in production method segment in the monoclonal antibody therapeutics industry
Human segment held a dominant share in source segment in the monoclonal antibody therapeutics industry
Oncology is likely to grow at significant CAGR in the monoclonal antibody therapeutics industry
The hospitals segment of the monoclonal antibody therapeutics industry is expected to register fastest growth during the forecast period.

Market Overview
The global monoclonal antibody (mAb) therapeutics market represents one of the most dynamic segments in modern medicine, revolutionizing the management of chronic diseases, autoimmune disorders, and particularly cancer. Monoclonal antibodies, which are laboratory-produced molecules designed to mimic the immune system’s ability to fight off harmful pathogens, have reshaped drug discovery and delivery paradigms due to their specificity, efficacy, and safety profiles.
The application of monoclonal antibodies spans a wide range of therapeutic areas including oncology, hematology, immunology, and ophthalmology, among others. Their capacity to precisely target antigens on diseased cells or tissues while minimizing off-target effects has positioned them as front-line therapies in conditions like rheumatoid arthritis, multiple sclerosis, breast cancer, non-Hodgkin's lymphoma, and age-related macular degeneration.
From blockbuster drugs like Adalimumab (Humira) and Trastuzumab (Herceptin) to next-generation immune checkpoint inhibitors like Nivolumab (Opdivo) and Pembrolizumab (Keytruda), monoclonal antibody therapeutics have emerged as critical tools in both chronic and rare disease management. The emergence of bispecific antibodies and antibody-drug conjugates (ADCs) further underscores the potential of this class of biologics.
With global health systems increasingly favoring targeted therapies that deliver superior outcomes with lower systemic toxicity, monoclonal antibody therapies are positioned to maintain robust demand in the years ahead. Furthermore, advances in recombinant DNA technology, bioprocessing, and regulatory frameworks are accelerating their development and commercial rollout.
Major Trends in the Market

Growth of biosimilar monoclonal antibodies: Patent expirations of blockbuster biologics are fostering a surge in biosimilar development, improving affordability and access.

Rising focus on oncology and immunotherapy: Cancer remains the largest and fastest-growing therapy area, particularly with checkpoint inhibitors and personalized mAb regimens.

Emergence of subcutaneous and self-administration formats: Convenience and patient compliance are driving innovations in mAb delivery routes.

Expanding pipeline of bispecific and trispecific antibodies: Multi-targeted mAbs are evolving rapidly, offering greater efficacy in complex diseases.

Increased adoption of in-vitro production platforms: Scalable, cell-based production systems are preferred for better control, efficiency, and lower contamination risk.

Collaborations between biotech and pharma giants: Licensing agreements and co-development initiatives are fueling faster innovation and broader distribution.

Use of AI and bioinformatics in antibody discovery: Computational platforms are reducing time-to-market by predicting structures and antigen affinity.

Government and private funding in rare disease treatments: Financial incentives and orphan drug designations are fostering innovation in niche therapeutic areas.

Monoclonal Antibody Therapeutics Market Report Scope

Report Attribute
Details

Market Size in 2024
USD 267.47 Billion

Market Size by 2033
USD 919.06 Billion

Growth Rate From 2024 to 2033
CAGR of 14.7%

Base Year
2023

Forecast Period
2024 to 2033

Segments Covered
By Production Method, By Sources, By Route of Administration, By Therapy Area, By End User , By Region

Market Analysis (Terms Used)
Value (US$ Million/Billion) or (Volume/Units)

Report Coverage
Revenue forecast, company ranking, competitive landscape, growth factors, and trends

Key Companies Profiled
F. Hoffmann-La Roche Ltd (Switzerland), Abbvie Inc. (US), Johnson & Johnson Services, Inc. (US), Merck & Co., Inc. (US), Bristol Myers Squibb Company (US), AstraZeneca (UK), Sanofi (France), Novartis AG (Switzerland), Amgen Inc. (US), Takeda Pharmaceutical Company Limited (Japan), GSK plc. (UK), Eli Lilly and Company (US), Regeneron Pharmaceuticals Inc. (US), Biogen (US), UCB S.A. (Belgium), Boehringer Ingelheim International GmbH (Germany), Y-mAbs Therapeutics Inc. (US), Teva Pharmaceutical Industries Ltd. (Israel) and among others.

Market Driver: Rising Prevalence of Chronic and Autoimmune Diseases
One of the strongest drivers of the monoclonal antibody therapeutics market is the escalating global prevalence of chronic and autoimmune diseases. Conditions like Crohn’s disease, rheumatoid arthritis, psoriasis, multiple sclerosis, and lupus affect millions worldwide, often requiring long-term, targeted treatment. Unlike traditional immunosuppressants, monoclonal antibodies offer disease-modifying action with reduced side effects, making them the therapy of choice in many clinical guidelines.
In the U.S. alone, it’s estimated that over 24 million people live with autoimmune conditions. Drugs like Adalimumab (anti-TNF) and Tocilizumab (IL-6 receptor blocker) have revolutionized disease management in these populations. Their ability to directly inhibit inflammatory pathways has translated into improved patient outcomes, reduced hospitalization rates, and better quality of life. As diagnostic capabilities improve and healthcare systems adopt value-based care models, mAbs are poised to gain even more traction.
Market Restraint: High Cost and Accessibility Issues
Despite their efficacy, monoclonal antibody therapeutics come with a significant cost burden, both for healthcare systems and patients. The complex and resource-intensive nature of biologics manufacturing—requiring specialized cell lines, bioreactors, and strict quality controls—contributes to high prices. Moreover, logistical challenges in cold chain distribution and administration (often intravenous) further add to the cost.
In regions with underdeveloped healthcare infrastructure or limited insurance coverage, access to monoclonal antibody therapies remains restricted. This issue is exacerbated in low- and middle-income countries, where even generic medications struggle to reach populations consistently. Even in developed economies, insurers may limit access or require extensive prior authorization for high-cost mAb therapies. This economic disparity continues to pose a significant barrier to widespread adoption.
Market Opportunity: Rapid Expansion of Oncology mAb Applications
A transformative opportunity for the monoclonal antibody therapeutics market lies in the oncology segment. Monoclonal antibodies have changed the landscape of cancer treatment by providing precision-targeted therapies that attack tumors while sparing healthy tissues. From HER2-positive breast cancer to advanced lung, kidney, and skin cancers, mAbs are integrated into treatment regimens as monotherapy or in combination with chemotherapy and radiation.
Checkpoint inhibitors like Keytruda (Pembrolizumab) and Opdivo (Nivolumab) have shown unprecedented results in metastatic melanoma and non-small cell lung cancer. Their success is prompting further research into combining mAbs with cell therapies, vaccines, and small-molecule inhibitors. With the global oncology burden projected to exceed 29 million cases by 2040, the scope for monoclonal antibody innovation in this space is immense. The rise of biomarkers and companion diagnostics will further personalize mAb treatment strategies, unlocking a new wave of opportunities.
Segmental Analysis
By Production Method
In-vitro production methods dominate the monoclonal antibody therapeutics market, owing to their scalability, safety, and compatibility with regulatory standards. These methods, primarily based on recombinant DNA technology and cell culture systems (e.g., CHO cells), allow precise control over antibody characteristics like glycosylation patterns and affinity. Leading manufacturers prefer in-vitro systems to produce large volumes of high-purity mAbs needed for chronic treatments. Their usage is also safer, eliminating animal welfare concerns associated with in-vivo methods. Moreover, in-vitro platforms support faster turnaround for clinical trials and commercial scale-ups, making them indispensable to pipeline efficiency.
In-vivo production, while largely phased out from mainstream manufacturing, still holds relevance in research environments and for developing niche or orphan biologics. Some animal-derived antibody production methods remain in use for rare diseases or for producing polyclonal antibodies, which may be used in diagnostics or emergency therapeutics. Despite being slower and less controlled, in-vivo methods are sometimes seen in early-stage research, especially where cost or infrastructure limits access to bioreactors.
By Sources
Humanized monoclonal antibodies continue to dominate the market due to their balance between efficacy and reduced immunogenicity. Developed through genetic engineering techniques that graft non-human antigen-binding regions onto human antibody frameworks, these mAbs significantly reduce the risk of adverse immune responses. Medications like Trastuzumab and Bevacizumab have set the benchmark in cancer and ophthalmology respectively, showcasing the therapeutic utility of humanized antibodies.
Fully human monoclonal antibodies are the fastest-growing source segment, supported by advancements in transgenic animal models and phage display technologies. Drugs like Adalimumab (Humira), the world's best-selling drug for years, exemplify this class. Their lack of foreign protein segments minimizes allergic reactions and anti-drug antibody (ADA) formation, which is especially valuable in chronic treatments. With evolving regulatory support and robust clinical pipelines, the transition toward fully human mAbs is accelerating.
By Route of Administration
Intravenous (IV) administration dominates the monoclonal antibody therapeutics market, especially in hospital-based settings and for acute care patients. IV delivery ensures rapid bioavailability and precise dosing, making it the preferred method in oncology, hematology, and intensive care units. Many first-generation mAbs were formulated for IV use due to stability constraints and because healthcare professionals could monitor for immediate allergic reactions.
Subcutaneous (SC) delivery is the fastest-growing route of administration due to increasing patient preference for home-based therapy and convenience. SC formulations reduce clinic visits, lower infusion times, and improve patient compliance—especially important in autoimmune diseases. Products like Dupilumab for atopic dermatitis and Benralizumab for asthma are leading the shift toward SC injections. Drug-device combinations, such as prefilled syringes and auto-injectors, are being adopted rapidly, particularly in Western markets.
By Therapy Area
Oncology remains the dominant therapeutic area, accounting for the largest revenue share in the monoclonal antibody therapeutics market. mAbs are used extensively in the treatment of breast, lung, colorectal, and hematologic malignancies. Drugs like Rituximab (CD20-targeted) and Trastuzumab (HER2-targeted) are widely used, while newer agents like Atezolizumab and Durvalumab expand treatment options via immune checkpoint pathways. As personalized oncology expands through biomarker-guided treatment protocols, the demand for novel mAbs will continue to climb.
Ophthalmology is emerging as the fastest-growing therapy area, largely driven by aging populations and increasing cases of macular degeneration and diabetic retinopathy. Anti-VEGF monoclonal antibodies like Ranibizumab (Lucentis) and Bevacizumab (used off-label) have redefined standard-of-care treatment in retinal diseases. Newer, longer-acting formulations are being developed to reduce injection frequency and improve patient adherence.
By End User
Hospitals dominate the end-user segment as mAb therapies often require clinical supervision during administration, especially for IV infusions. Hospital settings offer the infrastructure needed for cold storage, controlled infusion rates, and immediate management of hypersensitivity reactions. Oncology departments, transplant centers, and rheumatology clinics within hospitals are key usage points for monoclonal antibodies.
Long-term care facilities, while smaller in market share, are seeing a steady rise in monoclonal antibody administration due to aging populations and increased prevalence of chronic conditions like Alzheimer’s and arthritis. SC mAbs suitable for at-home or community-based care are enabling this shift. These facilities also benefit from mAbs that prevent hospital readmissions by maintaining disease control in elderly patients with multiple comorbidities.
Regional Analysis
North America Dominates the Global Market
North America particularly the United States dominates the monoclonal antibody therapeutics market, accounting for the largest share in terms of revenue and clinical activity. The region benefits from a strong pharmaceutical infrastructure, leading biotech firms, robust regulatory frameworks, and a high incidence of chronic and oncologic diseases. The U.S. FDA has been at the forefront of fast-tracking mAb approvals under initiatives like Breakthrough Therapy Designation. Companies like Amgen, AbbVie, and Bristol-Myers Squibb lead the way in developing blockbuster biologics. Additionally, widespread insurance coverage and a culture of early biologics adoption contribute to market dominance.
Asia-Pacific is the Fastest Growing Region
Asia-Pacific is emerging as the fastest-growing region due to rising healthcare investments, improving access to biologics, and increasing prevalence of cancer and autoimmune diseases. Countries like China, Japan, and India are actively expanding their biopharma manufacturing capacity and regulatory pathways to accommodate monoclonal antibody production. China's local mAb innovation is supported by companies like Innovent Biologics and Junshi Biosciences, which are gaining global attention for oncology and COVID-19 antibody therapies. As healthcare infrastructure improves and biologic approvals increase, the region is poised to be a critical growth engine for global mAb sales.
Monoclonal Antibody Therapeutics Market Top Key Companies:

F. Hoffmann-La Roche Ltd (Switzerland)
Abbvie Inc. (US)
Johnson & Johnson Services, Inc. (US)
Merck & Co., Inc. (US)
Bristol Myers Squibb Company (US)
AstraZeneca (UK)
Sanofi (France)
Novartis AG (Switzerland)
Amgen Inc. (US)
Takeda Pharmaceutical Company Limited (Japan)
GSK plc. (UK)
Eli Lilly and Company (US)
Regeneron Pharmaceuticals Inc. (US)
Biogen (US)
UCB S.A. (Belgium)
Boehringer Ingelheim International GmbH (Germany)
Y-mAbs Therapeutics Inc. (US)
Teva Pharmaceutical Industries Ltd. (Israel) and among others.

Monoclonal Antibody Therapeutics Market Report Segmentation
This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Nova one advisor, Inc. has segmented the Monoclonal Antibody Therapeutics market.
By Production Method

In-Vitro
In-Vivo

By Sources

Human
Humanized
Chimeric
Other Sources

By Route of Administration

Intravenous
Subcutaneous
Other Route of Administration

By Therapy Area

Autoimmune & Inflammatory Disorders
Oncology
Hematology
Ophthalmology
Other Therapy Areas

By End User

Hospitals
Long-term Care Facilities
Other End Users

By Region

North America
Europe
Asia-Pacific
Latin America
Middle East & Africa (MEA)

Table of Contents

453 Pages
Chapter 1. Introduction
1.1. Report Description and Scope
1.2. Research Scope
1.3. Research Methodology
1.3.1. Market Research Process
1.3.2. Market Research Methodology
Chapter 2. Executive Summary
2.1. Global Monoclonal Antibody Therapeutics Market, 2015 - 2023 (USD Billion)
2.2. Global Monoclonal Antibody Therapeutics Market: Snapshot
Chapter 3. Monoclonal Antibody Therapeutics Market- Market Dynamics
3.1. Introduction
3.2. Market Drivers
3.2.1. Global Monoclonal Antibody Therapeutics Market Drivers: Impact Analysis
3.2.2. Growing Monoclonal Antibody Therapeutics Consumption in Developing Countries
3.2.3. Changing Consumption Habits of Monoclonal Antibody Therapeutics
3.3. Market Restraints
3.3.1. Global Monoclonal Antibody Therapeutics Market Restraints: Impact Analysis
3.3.2. High Taxation in Monoclonal Antibody Therapeutics Business and Trade
3.4. Opportunities
3.4.1. Innovative Products with Flavored Monoclonal Antibody Therapeutics
3.5. Porter's Five Forces Analysis
3.5.1. Bargaining Power of Suppliers
3.5.2. Bargaining Power of Buyers
3.5.3. Threat from New Entrants
3.5.4. Threat from New Substitutes
3.5.5. Degree of Competition
3.6. Market Attractiveness Analysis
3.6.1. Market Attractiveness Analysis, by Application Segment
3.6.2. Market Attractiveness Analysis, by Source Segment
3.6.3. Market Attractiveness Analysis, by End User Segment
3.6.4. Market Attractiveness Analysis, by Regional Segment
Chapter 4. Global Monoclonal Antibody Therapeutics Market- Competitive Landscape
4.1. Company Market Share Analysis
4.1.1. Global Monoclonal Antibody Therapeutics Market: Company Market Share, 2017
4.2. Strategic Development
4.2.1. Acquisitions & Mergers
4.2.2. New Product Launch
4.2.3. Agreements, Partnerships, Collaborations and Joint Ventures
4.2.4. Research and Development and Regional Expansion
4.3. Price Trend Analysis
Chapter 5. Global Monoclonal Antibody Therapeutics Market- Application Segment Analysis
5.1. Global Monoclonal Antibody Therapeutics Market: Application Overview
5.1.1. Global Monoclonal Antibody Therapeutics Market Revenue Share, by Application, 2017 and 2023
5.2. Cancer
5.2.1. Global Monoclonal Antibody Therapeutics Market for Cancer, 2015 - 2023 (USD Billion)
5.3. Autoimmune Diseases
5.3.1. Global Monoclonal Antibody Therapeutics Market for Autoimmune Diseases, 2015 - 2023 (USD Billion)
5.4. Infection
5.4.1. Global Monoclonal Antibody Therapeutics Market for Infection, 2015 - 2023 (USD Billion)
5.5. Hematological Diseases
5.5.1. Global Monoclonal Antibody Therapeutics Market for Hematological Diseases, 2015 - 2023 (USD Billion)
5.6. Others
5.6.1. Global Monoclonal Antibody Therapeutics Market for Others, 2015 - 2023 (USD Billion)
Chapter 6. Global Monoclonal Antibody Therapeutics Market- Source Segment Analysis
6.1. Global Monoclonal Antibody Therapeutics Market: Source Overview
6.1.1. Global Monoclonal Antibody Therapeutics Market Revenue Share, by Source, 2017 and 2023
6.2. Human
6.2.1. Global Monoclonal Antibody Therapeutics Market for Human, 2015 - 2023 (USD Billion)
6.3. Humanized
6.3.1. Global Monoclonal Antibody Therapeutics Market for Humanized, 2015 - 2023 (USD Billion)
6.4. Chimeric
6.4.1. Global Monoclonal Antibody Therapeutics Market for Chimeric, 2015 - 2023 (USD Billion)
6.5. Others
6.5.1. Global Monoclonal Antibody Therapeutics Market for Others, 2015 - 2023 (USD Billion)
Chapter 7. Global Monoclonal Antibody Therapeutics Market- End User Segment Analysis
7.1. Global Monoclonal Antibody Therapeutics Market: End User Overview
7.1.1. Global Monoclonal Antibody Therapeutics Market Revenue Share, by End User, 2017 and 2023
7.2. Hospitals
7.2.1. Global Monoclonal Antibody Therapeutics Market for Hospitals, 2015 - 2023 (USD Billion)
7.3. Private Clinics
7.3.1. Global Monoclonal Antibody Therapeutics Market for Private Clinics, 2015 - 2023 (USD Billion)
7.4. Research Institutes
7.4.1. Global Monoclonal Antibody Therapeutics Market for Research Institutes, 2015 - 2023 (USD Billion)
Chapter 8. Global Monoclonal Antibody Therapeutics Market- Regional Segment Analysis
8.1. Global Monoclonal Antibody Therapeutics Market: Regional Overview
8.1.1. Global Monoclonal Antibody Therapeutics Market Revenue Share, by Region, 2017 And 2023
8.2. North America
8.2.1. North America Monoclonal Antibody Therapeutics Market, 2015 - 2023 (USD Billion)
8.2.2. North America Monoclonal Antibody Therapeutics Market Revenue, by Application, 2015 - 2023 (USD Billion)
8.2.3. North America Monoclonal Antibody Therapeutics Market Revenue, by Source, 2015 - 2023 (USD Billion)
8.2.4. North America Monoclonal Antibody Therapeutics Market Revenue, by End User, 2015 - 2023 (USD Billion)
8.2.5. U.S.
8.2.5.1. U.S. Monoclonal Antibody Therapeutics Market Revenue, by Application, 2015 - 2023 (USD Billion)
8.2.5.2. U.S. Monoclonal Antibody Therapeutics Market Revenue, by Source, 2015 - 2023 (USD Billion)
8.2.5.3. U.S. Monoclonal Antibody Therapeutics Market Revenue, by End User, 2015 - 2023 (USD Billion)
8.2.6. Rest of North America
8.2.6.1. Rest of North America Monoclonal Antibody Therapeutics Market Revenue, by Application, 2015 - 2023 (USD Billion)
8.2.6.2. Rest of North America Monoclonal Antibody Therapeutics Market Revenue, by Source, 2015 - 2023 (USD Billion)
8.2.6.3. Rest of North America Monoclonal Antibody Therapeutics Market Revenue, by End User, 2015 - 2023 (USD Billion)
8.3. Europe
8.3.1. Europe Monoclonal Antibody Therapeutics Market, 2015 - 2023 (USD Billion)
8.3.2. Europe Monoclonal Antibody Therapeutics Market Revenue, by Application, 2015 - 2023 (USD Billion)
8.3.3. Europe Monoclonal Antibody Therapeutics Market Revenue, by Source, 2015 - 2023 (USD Billion)
8.3.4. Europe Monoclonal Antibody Therapeutics Market Revenue, by End User, 2015 - 2023 (USD Billion)
8.3.5. UK
8.3.5.1. UK Monoclonal Antibody Therapeutics Market Revenue, by Application, 2015 - 2023 (USD Billion)
8.3.5.2. UK Monoclonal Antibody Therapeutics Market Revenue, by Source, 2015 - 2023 (USD Billion)
8.3.5.3. UK Monoclonal Antibody Therapeutics Market Revenue, by End User, 2015 - 2023 (USD Billion)
8.3.6. Germany
8.3.6.1. Germany Monoclonal Antibody Therapeutics Market Revenue, by Application, 2015 - 2023 (USD Billion)
8.3.6.2. Germany Monoclonal Antibody Therapeutics Market Revenue, by Source, 2015 - 2023 (USD Billion)
8.3.6.3. Germany Monoclonal Antibody Therapeutics Market Revenue, by End User, 2015 - 2023 (USD Billion)
8.3.7. France
8.3.7.1. France Monoclonal Antibody Therapeutics Market Revenue, by Application, 2015 - 2023 (USD Billion)
8.3.7.2. France Monoclonal Antibody Therapeutics Market Revenue, by Source, 2015 - 2023 (USD Billion)
8.3.7.3. France Monoclonal Antibody Therapeutics Market Revenue, by End User, 2015 - 2023 (USD Billion)
8.3.8. Rest of Europe
8.3.8.1. Rest of Europe Monoclonal Antibody Therapeutics Market Revenue, by Application, 2015 - 2023 (USD Billion)
8.3.8.2. Rest of Europe Monoclonal Antibody Therapeutics Market Revenue, by Source, 2015 - 2023 (USD Billion)
8.3.8.3. Rest of Europe Monoclonal Antibody Therapeutics Market Revenue, by End User, 2015 - 2023 (USD Billion)
8.4. Asia Pacific
8.4.1. Asia Pacific Monoclonal Antibody Therapeutics Market, 2015 - 2023 (USD Billion)
8.4.2. Asia Pacific Monoclonal Antibody Therapeutics Market Revenue, by Application, 2015 - 2023 (USD Billion)
8.4.3. Asia Pacific Monoclonal Antibody Therapeutics Market Revenue, by Source, 2015 - 2023 (USD Billion)
8.4.4. Asia Pacific Monoclonal Antibody Therapeutics Market Revenue, by End User, 2015 - 2023 (USD Billion)
8.4.5. China
8.4.5.1. China Monoclonal Antibody Therapeutics Market Revenue, by Application, 2015 - 2023 (USD Billion)
8.4.5.2. China Monoclonal Antibody Therapeutics Market Revenue, by Source, 2015 - 2023 (USD Billion)
8.4.5.3. China Monoclonal Antibody Therapeutics Market Revenue, by End User, 2015 - 2023 (USD Billion)
8.4.6. Japan
8.4.6.1. Japan Monoclonal Antibody Therapeutics Market Revenue, by Application, 2015 - 2023 (USD Billion)
8.4.6.2. Japan Monoclonal Antibody Therapeutics Market Revenue, by Source, 2015 - 2023 (USD Billion)
8.4.6.3. Japan Monoclonal Antibody Therapeutics Market Revenue, by End User, 2015 - 2023 (USD Billion)
8.4.7. India
8.4.7.1. India Monoclonal Antibody Therapeutics Market Revenue, by Application, 2015 - 2023 (USD Billion)
8.4.7.2. India Monoclonal Antibody Therapeutics Market Revenue, by Source, 2015 - 2023 (USD Billion)
8.4.7.3. India Monoclonal Antibody Therapeutics Market Revenue, by End User, 2015 - 2023 (USD Billion)
8.4.8. Rest of Asia Pacific
8.4.8.1. Rest of Asia Pacific Monoclonal Antibody Therapeutics Market Revenue, by Application, 2015 - 2023 (USD Billion)
8.4.8.2. Rest of Asia Pacific Monoclonal Antibody Therapeutics Market Revenue, by Source, 2015 - 2023 (USD Billion)
8.4.8.3. Rest of Asia Pacific Monoclonal Antibody Therapeutics Market Revenue, by End User, 2015 - 2023 (USD Billion)
8.5. Latin America
8.5.1. Latin America Monoclonal Antibody Therapeutics Market, 2015 - 2023 (USD Billion)
8.5.2. Latin America Monoclonal Antibody Therapeutics Market Revenue, by Application, 2015 - 2023 (USD Billion)
8.5.3. Latin America Monoclonal Antibody Therapeutics Market Revenue, by Source, 2015 - 2023 (USD Billion)
8.5.4. Rest of North America Monoclonal Antibody Therapeutics Market Revenue, by End User, 2015 - 2023 (USD Billion)
8.5.5. Brazil
8.5.5.1. Brazil Monoclonal Antibody Therapeutics Market Revenue, by Application, 2015 - 2023 (USD Billion)
8.5.5.2. Brazil Monoclonal Antibody Therapeutics Market Revenue, by Source, 2015 - 2023 (USD Billion)
8.5.5.3. Brazil Monoclonal Antibody Therapeutics Market Revenue, by End User, 2015 - 2023 (USD Billion)
8.5.6. Rest of Latin America
8.5.6.1. Rest of Latin America Monoclonal Antibody Therapeutics Market Revenue, by Application, 2015 - 2023 (USD Billion)
8.5.6.2. Rest of Latin America Monoclonal Antibody Therapeutics Market Revenue, by Source, 2015 - 2023 (USD Billion)
8.5.6.3. Rest of Latin America Monoclonal Antibody Therapeutics Market Revenue, by End User, 2015 - 2023 (USD Billion)
8.6. Middle East and Africa
8.6.1. Middle East and Africa Monoclonal Antibody Therapeutics Market, 2015 - 2023 (USD Billion)
8.6.2. Middle East and Africa Monoclonal Antibody Therapeutics Market Revenue, by Application, 2015 - 2023 (USD Billion)
8.6.3. Middle East and Africa Monoclonal Antibody Therapeutics Market Revenue, by Source, 2015 - 2023 (USD Billion)
8.6.4. Middle East and Africa Monoclonal Antibody Therapeutics Market Revenue, by End User, 2015 - 2023 (USD Billion)
Chapter 9. Company Profile
9.1. Pfizer Inc.
9.1.1. Overview
9.1.2. Financials
9.1.3. Product Portfolio
9.1.4. Business Strategy
9.1.5. Recent Developments
9.2. Bayer AG
9.2.1. Overview
9.2.2. Financials
9.2.3. Product Portfolio
9.2.4. Business Strategy
9.2.5. Recent Developments
9.3. Sanofi
9.3.1. Overview
9.3.2. Financials
9.3.3. Product Portfolio
9.3.4. Business Strategy
9.3.5. Recent Developments
9.4. Merck & Co., Inc.
9.4.1. Overview
9.4.2. Financials
9.4.3. Product Portfolio
9.4.4. Business Strategy
9.4.5. Recent Developments
9.5. GlaxoSmithKline Plc.
9.5.1. Overview
9.5.2. Financials
9.5.3. Product Portfolio
9.5.4. Business Strategy
9.5.5. Recent Developments
9.6. F. Hoffmann-La Roche Ltd.
9.6.1. Overview
9.6.2. Financials
9.6.3. Product Portfolio
9.6.4. Business Strategy
9.6.5. Recent Developments
9.7. Novartis AG
9.7.1. Overview
9.7.2. Financials
9.7.3. Product Portfolio
9.7.4. Business Strategy
9.7.5. Recent Developments
9.8. Holdings AbbVie Inc.
9.8.1. Overview
9.8.2. Financials
9.8.3. Product Portfolio
9.8.4. Business Strategy
9.8.5. Recent Developments
How Do Licenses Work?
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.